NRIX

BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company's investigational oral Bruton's tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.

Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by an additional two years.

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs).

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.